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A survey of the outcome of prophylaxis, on-demand or
combined treatment in 20–35 year old men with severe
haemophilia in four European countries
D. NOONE,* B. O MAHONY* and L. PRIHODOVA
*Irish Haemophilia Society, Cathedral Court, Ireland, Dublin; and Medical Faculty, Graduate School, Kosice Institute for Society and Health, PJ Safarik
University, Kosice, Slovak Republic
For children with severe haemophilia, prophylaxis is recognized as
the optimum standard of care [1] [2]. It is also one of the principles
of Haemophilia care espoused by the European Association for
Haemophilia and Allied Disorders (EAHAD) [3]. However, the
continuation of prophylactic therapy into adulthood is being more
closely scrutinized on the grounds of benefit and cost. This study was
carried out to examine the long-term effects of prophylaxis and the
continuing benefit of the therapy in adulthood. National Haemo-
philia patient organizations in Ireland, UK, France and Sweden were
asked to participate by randomly selecting 20 severe haemophilia
patients between 20 and 35 years from their database. Of the total of
80 questionnaires, 58 (72.5%) responses were received either by mail
or by phone interview. Ireland provided 19, UK provided nine,
France provided 10 and Sweden provided 20 responses. The four
countries were chosen based on their access to treatment for patients
with severe haemophilia. Swedish patients with severe haemophilia
have been treated with prophylaxis since the late 1970s. Ireland,
France and the UK introduced prophylaxis in the mid 1990s. The
study examined the differences in medical outcomes and quality-of-
life in patients who had full access to primary prophylaxis, entirely
on-demand or combinations of therapies. Information on age,
country and employment status and responses to an EQ5D ques-
tionnaire were collected. Medical data was also collected on type and
severity of haemophilia, treatment regime (prophylaxis vs. on-de-
mand), bleeds per year, target joints, major bleeds (e.g. ilio-psoas or
intercranial) and days missed from work/college per year. The pri-
mary analysis evaluated the differences between the four countries,
and the secondary analysis examined the differences as a proportion
of life spent on prophylaxis in comparison to on-demand therapy.
The mean age was 27.5 ± 4.7 years. In the primary analysis of the
individual countries (Table 1a), patients in Sweden have spent a
significantly higher percentage of their life on prophylaxis (P £ 0.05),
showed the lowest number of bleeds/year, lowest presence of target
joints (P £ 0.001) and major bleeds (P £ 0.005), lowest number of
days missed from work/college, higher scores in Mobility (EQ5D)
(P £ 0.05) and highest utility value. The secondary analysis (Ta-
ble 1b) confirmed these findings. Patients always treated with pro-
phylaxis reported significantly lower number of bleeds/year than
patients treated entirely or primarily on-demand (P £ 0.05), signifi-
cantly lower presence of target joints (P £ 0.001) and higher score in
mobility (P £ 0.005). Of the respondents who had received prophy-
laxis all of their lives, five reported major bleeds at some point, and
five reported target joints without specifying that most bleeds occur
in these joints. Three of each of these reported both target joints and
major bleeds. No information on lifestyle or compliance was col-
lected. Patients treated on-demand reported significantly higher
number of days missed from work than all other groups (P £ 0.05)
and significantly lower score in EQ5D dimension Self-care
(P £ 0.05). The reported average number of bleeds/year for Sweden
and France of 3.2 and 20.1, respectively, are broadly consistent with
previous studies [4,5]. The results in the primary analysis for France,
UK and Ireland and in the secondary analysis for the on-demand
group are also similar to other published work [6, 7]. Hence, the
results in this study support the view that prophylaxis started at a
young age and continued into adulthood is an extremely effective
treatment for patients with severe haemophilia. Four patients who
were treated using prophylaxis switched to on-demand therapy and
subsequently reverted to prophylaxis. Nine patients (22%), who had
been treated primarily with on-demand therapy have now changed to
prophylaxis treatment. Respondents in both of these groups reported
that this change took place due to increased bleeding episodes and/or
joint problems that were developing when treated with on-demand
therapy. When asked about days missed from work, there was a
significant difference between countries. Swedish respondents re-
ported a mean 0.5 days missed/year from work or college for reasons
related to haemophilia. In Ireland and the UK, the days missed were
5 and 6.6 days respectively. With the French respondents, the mean
time missed from work or college for reasons related to haemophilia
was 15 days. This number was dramatically increased by two pa-
tients in the group not being able to attend work or college for
6 months following orthopaedic operations. For adults who have
been treated with on-demand therapy, a requirement for orthopaedic
surgery or joint replacement is not uncommon. This is further sup-
ported when the treatment regime was examined. Patients on pro-
phylaxis missed a mean of 0.7 days per year and patients on-demand
missed 19.2 days. The results from the EQ5D demonstrate the clear
benefits of long-term prophylaxis over on-demand therapy. A num-
ber of studies on cost effectiveness [8–10] have reported the differ-
ence in utility values between prophylaxis and on-demand of 0.03
and 0.09. This study has shown that the benefit of prophylaxis
continued into adulthood increases the utility value by a more sig-
nificant 0.16–0.20. Overall, on-demand treatment results in a lower
utility value in relation to quality-of-life for people with severe
haemophilia. Prophylaxis started at an early age and continued into
adulthood results in less bleeding, less damage to joints and less time
missed at work. Prophylaxis increases mobility and the ability to do
everyday activities and improves the health-related quality of life of
people with severe haemophilia. It would be beneficial to extend this
survey in the future to gather data on a larger number of people with
Haemophilia from a larger number of countries and the authors plan
to do this. It would be interesting to extend this survey to countries
where distinctly different prophylaxis regimes are used and to
countries that use low levels of FVIII per capita to assess what may
well be, in effect, a baseline utility figure.
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Mutations in coagulation factor XIII subunit A in severe
factor XIII deficiency patients: five novel mutations detected
S. SHANBHAG, S. SHETTY and K. GHOSH
National Institute of Immunohaematology (ICMR), Mumbai, India
Congenital factor XIII (FXIII) deficiency is a rare autosomal recessive
disorder affecting one in 1–5 million individuals, the prevalence of
which is higher in countries where consanguineous marriages are
common [1]. It is a serious bleeding diathesis, the common symptoms
being bleeding from the umbilical stump, prolonged bleeding postin-
jury, menorrhagia, poor healing of wounds, intra cranial bleed and
spontaneous abortions. FXIII deficiency is usually attributed to
mutations in the factor 13A (F13A) gene which is located in chro-
mosome 6, at p24-25 [2]. It spans 160 kb and consists of 15 exons
separated by 14 introns. Sixty-nine unique mutations (34 missense, 21
deletions/insertions, 9 splice site and 5 nonsense) in F13A gene have
been reported in the Factor 13 mutation database (http://www.f13-
database.de/). Detection of these mutations is important to study the
molecular basis of FXIII deficiency and also for genetic diagnosis in
affected families.
In this report, we have studied mutations in seven FXIII-deficient
patients who were so diagnosed on the basis of their clinical history,
normal screening coagulation values and clot solubility assays [3]. Five
of seven patients had history of first degree consanguinity among
parents. Genomic DNA of the patients was extracted from citrated
blood samples by the standard phenol chloroform method. F13A gene
was screened for mutations by PCR and direct sequencing using ABI
3130XL sequencer. The amino acid positions were reported according
to Ichinose et al. [4]. The deleterious effect of the novel mutations was
confirmed by studying degree of conservation of the mutated amino














France 20.1 100 80 15.0 0.74
Ireland 16.5 94* 68 5.0 0.68
Sweden 3.2 25 20 0.5 0.93
UK 17.5 100 44 6.6 0.76
(b)
Group 1 (100% on prophylaxis) 3.2 26.3 26.3 0.9 0.88
Group 2 (50–99% on prophylaxis) 11.5 81.0 59.1 3.6 0.77
Group 3 (1–50% on prophylaxis) 20.1 93.8 56.2 3.6 0.79
Group 4 (0% on prophylaxis) 26.5 88.9 48.5 19.2 0.72
*Of respondents from Ireland, UK and France only one person (20 years old) does not report target joints.
He was on prophylaxis until he was 18 and has now switched to on-demand.
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